RBL2
Retinoblastoma-like protein 2
Protein Summary
Key regulator of entry into cell division. Directly involved in heterochromatin formation by maintaining overall chromatin structure and, in particular, that of constitutive heterochromatin by stabilizing histone methylation. Recruits and targets histone methyltransferases KMT5B and KMT5C, leading to epigenetic transcriptional repression. Controls histone H4 'Lys-20' trimethylation. Probably acts as a transcription repressor by recruiting chromatin-modifying enzymes to promoters. Potent inhibitor of E2F-mediated trans-activation, associates preferentially with E2F5. Binds to cyclins A and E. Binds to and may be involved in the transforming capacity of the adenovirus E1A protein. May act as a tumor suppressor.
- ENST00000262133
- ENSP00000262133
- ENSG00000103479
- RB2
- Rb2
- P130
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
hub protein | 0.95 | ||
protein domain | 0.85 | ||
kinase | 0.83 | ||
transcription factor binding site profile | 0.82 | ||
viral protein | 0.8 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 1070.97 (req: < 5)
Gene RIFs: 76 (req: <= 3)
Antibodies: 432 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 1070.97 (req: >= 5)
Gene RIFs: 76 (req: > 3)
Antibodies: 432 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 12
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0